Arnold Susan Elizabeth 4
4 · PhaseBio Pharmaceuticals Inc · Filed Oct 24, 2018
Insider Transaction Report
Form 4
Arnold Susan Elizabeth
VP, Preclinical and Chem.
Transactions
- Conversion
Common Stock
2018-10-22+2,306→ 2,306 total - Conversion
Series B Preferred Stock
2018-10-22−2,306→ 0 total→ Common Stock (2,306 underlying) - Exercise/Conversion
Series B Preferred Stock
2018-10-22$0.12/sh+103$12→ 2,306 total→ Common Stock (103 underlying) - Exercise/Conversion
Warrants to Purchase Series B Preferred Stock
2018-10-22−103→ 0 totalExercise: $0.12→ Series B Preferred Stock (103 underlying)
Footnotes (3)
- [F1]Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]Represents the exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- [F3]The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.